Strong Track Record

Our Strong Track Record of Helping Address Prescription Drug Abuse and Diversion

The opioid crisis is among our nation’s top public health challenges. Purdue Pharma continues to advance efforts and dedicate resources to address opioid abuse and diversion.


We support initiatives to address many dimensions of this complex problem, including:

  • The National Institutes of Health’s (NIH) public-private partnership focused on accelerating the development of treatments for opioid use disorder and non-opioid, non-addictive pain medications, as recommended by President Trump’s Opioid Commission.
  • The Governor’s Prevention Partnership of Connecticut, a public-private agency focused on education about youth issues, including substance abuse, to sponsor educational initiatives including public service announcements (PSAs).
  • RxPATROL®(Pattern Analysis Tracking Robberies and Other Losses), the first national database to track, analyze, and provide information on pharmacy theft and loss to law enforcement and the retail pharmacy network. Created by Purdue in 2003, today RxPATROL® has more than 13,600 registered users and helps law enforcement solve pharmacy crimes, and educate retail pharmacy leaders on how they can protect themselves, their businesses, and their customers.


We provide training, education, and materials to help address prescription drug abuse and diversion.

  • We partnered with the National Sheriffs’ Association (NSA) by funding their Saving Lives program. To date, more than 1,000 law enforcement officers and command staff have been trained to administer naloxone and naloxone overdose kits were distributed to 39 law enforcement agencies in 21 states. A recent report, issued by NSA in April 2018 estimates that NSA and Purdue have saved more than 175 lives since the program began in December 2015.
  • Our Law Enforcement Liaison & Education group provides training on abuse detection and deterrence to law enforcement officers throughout the country.
  • We support the National Association of Drug Diversion Investigators’ (NADDI) Law Enforcement Grant program, which provides resources to law enforcement to help address prescription drug abuse and diversion.


We advocate for the use of Prescription Drug Monitoring Programs (PDMPs) by healthcare professionals in states across the country.

  • We provided $3.1 million toward a public-private partnership with the Commonwealth of Virginia to integrate PDMP data and analysis into the electronic health record workflow of 18,000 doctors and nurses and 300 pharmacies.
  • We partnered with Project Lazarus and Safe Kids North Carolina to support state-wide medicine disposal activities and conduct systematic research to evaluate the impact of community-based prevention programs on opioid-related overdoses, abuse, and diversion.


We have recently made several corporate announcements related to our operations and corporate social responsibility (CSR) efforts. 

  • In October 2017, we joined the Prescription Drug Safety Network created by Everfi, the leading prevention education innovator. Through this coalition, Purdue supports efforts to bring prevention education regarding prescription drug misuse and abuse to high school students across the country.
  • In February 2018, we significantly reduced our commercial operation and announced that our field sales organization will no longer visit prescribers to discuss our opioid products. Through our Medical Affairs team, we will continue to support healthcare professionals who prescribe opioid analgesics to appropriate patients at the right dosage for the right duration. Product inquiries will also continue to be addressed through our Medical Affairs team.
  • In March 2018, we announced a new head of CSR. This role is responsible for building on existing public-private partnerships and collaborations while advancing efforts to address the opioid crisis beyond prevention and harm reduction and into the areas of treatment and recovery support.

For additional information on Purdue Pharma’s strong record of helping to address prescription drug abuse and diversion, please visit: